However, in breast cancer metastasis models, particularly in bone, tazemetostat and similar EZH2 inhibitors such as GSK126 have shown limited efficacy, likely due to EZH2’s non-catalytic functions, which remain active despite inhibition of its methyltransferase activity [196]. The gene discussed is EZH2; the disease is breast carcinoma.